COMP <GO>
AMLX vs PBLS // OPERATING MARGIN
Amylyx Pharmaceuticals Inc. (NASDAQ) VS. Parabilis Medicines Inc. (NASDAQ) • 15-METRIC TALLY: AMLX 2
— PBLS 0
■ METRIC PARITY
LAST: $28.68 (+2.17%) • MKT CAP: $3.60B
operating-margins
—
LAST: $28.70 (+1.88%) • MKT CAP: $3.50B
operating-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMLX VS. PBLS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AMLX | PBLS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.43% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin ACTIVE | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.9 | 48.5 | +3.40 | AMLX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.60B | $3.50B | $98.1M | AMLX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AMLX REV | PBLS REV | AMLX GROSS % | PBLS GROSS % | AMLX FCF | PBLS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$123.5M | — |
| FY 2024 | $87.4M | — | 93.2% | — | -$167.8M | — |
| FY 2023 | $380.8M | — | — | — | $11.9M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMLX // BETA —
PBLS // BETA —